Prediction of recruitment in randomized clinical trials (RECRUIT-IT)

Prediction of recruitment in randomized clinical trials (RECRUIT-IT)

Randomized clinical trials (RCTs) are considered standard to evaluate benefits and harms of health care interventions. Large RCTs are major undertakings that require enormous resources and coordination and are often not completed as planned. Even small RCTs require non-negligible resources and may deviate from their original expectations even more often. One out of four RCTs is prematurely discontinued for different reasons, poor recruitment is the most frequent reason for early discontinuation of RCTs. Such discontinued RCTs are also less likely to be published in medical journals. Early discontinuation for poor recruitment is problematic: First, the pertinent research question typically remains unanswered. Second, precious resources for clinical research are wasted if costly RCTs need to be discontinued because of overoptimistic recruitment assumptions, and, in particular, if whatever valid data and lessons are learned remain unpublished. Third, patients' trust and willingness to participate in clinical studies is compromised.A central question for investigators during planning and conducting RCTs is: Given the expected number of participating centres and number of patients per centre, how long will it take to recruit the target number of patients? Once the trial has started, the central question changes into: Given the recruitment data we have so far, how long will it take to recruit the target number of patients now?Therefore, evidence-based guidance and tools to predict and monitor recruitment of patients to RCTs are needed. Systematic empirical investigations and validations of proposed recruitment models is lacking. We therefore initiated the present international project on patient recruitment in RCTs (RECRUIT-IT) to provide evidence-based recommendations for the planning and monitoring of patient recruitment in RCTs.

[{ "PostingID": 74, "Title": "GSK-LOV111819", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered with Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects" },{ "PostingID": 103, "Title": "GSK-TOC110977", "Description": "A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL" },{ "PostingID": 121, "Title": "GSK-TRX109011", "Description": "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2" },{ "PostingID": 287, "Title": "GSK-NAI30028", "Description": "A Double-Blind,Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Children." },{ "PostingID": 295, "Title": "GSK-NAIB3002", "Description": "A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults." },{ "PostingID": 332, "Title": "GSK-105517/287", "Description": "Carvedilol Prospective Randomized Cumulative Survival Trial." },{ "PostingID": 394, "Title": "GSK-FLTA3025", "Description": "A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg twice daily, 500mcg twice daily, and placebo twice daily via the DISKUS® inhaler in subjects with chronic obstructive pulmonary disease (COPD)." },{ "PostingID": 417, "Title": "GSK-SCO30005", "Description": "A 13-week, double-blind, parallel group, multi-centre study to compare the bronchial anti-inflammatory activity of the combination of salmeterol/fluticasone propionate 50/500mcg twice daily compared with placebo twice daily in patients with Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 426, "Title": "GSK-SFCA3007", "Description": "A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulation of salmeterol 50mcg twice daily and fluticasone propionate 250mcg twice daily individually and in combination as compared to placebo in COPD patients." },{ "PostingID": 475, "Title": "GSK-49653/048", "Description": "A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus" },{ "PostingID": 478, "Title": "GSK-49653/231", "Description": "A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia" },{ "PostingID": 501, "Title": "GSK-AVA102670", "Description": "A 54-week, study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT-3)" },{ "PostingID": 522, "Title": "GSK-HZC110946", "Description": "A three-way incomplete block crossover study to investigate the 24-hour pulmonary function of three dosage strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in subjects with Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 1309, "Title": "ROCHE-BO17708", "Description": "A randomized, double-blind study of the effect of first line treatment with Avastin (bevacizumab) in combination with docetaxel on progression-free survival and disease response in patients with HER2 negative metastatic breast cancer" },{ "PostingID": 1350, "Title": "ROCHE-WA17822", "Description": "A randomized, double-blind study of safety and reduction in signs and symptoms during treatment with tocilizumab versus placebo, in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis" },{ "PostingID": 1367, "Title": "ROCHE-NT18435", "Description": "A randomized, double-blind study to compare the effect of up to 100 days, and up to 200 days, of treatment with Valcyte (valganciclovir) on prevention of cytomegalovirus disease in high-risk kidney allograft recipients" },{ "PostingID": 1374, "Title": "VIIV-CAL30001", "Description": "A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients" },{ "PostingID": 1378, "Title": "VIIV-ESS30009", "Description": "A phase III, randomized, open-label, multicenter study of the safety and efficacy of efavirenz versus tenofovir when administered in combination with the abacavir/lamivudine fixed-dose combination tablet as a once-daily regimen in antiretroviral-naive HIV-1 infected subjects." },{ "PostingID": 1391, "Title": "VIIV-APV100732", "Description": "A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks" },{ "PostingID": 1395, "Title": "VIIV-APV30001", "Description": "A Phase III, Randomized, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety and Tolerability of GW433908 (1400mg BID) and Nelfinavir (1250mg BID) Over 48 Weeks in Antiretroviral Therapy-Naïve HIV-1 Infected Adults" },{ "PostingID": 1409, "Title": "BI-205.251", "Description": "12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD" },{ "PostingID": 1417, "Title": "GSK-HGS1006-C1057", "Description": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)" },{ "PostingID": 1439, "Title": "GSK-ARIB3004 Double-blind Phase", "Description": "A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension" },{ "PostingID": 1445, "Title": "GSK-FAP30008", "Description": "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy" },{ "PostingID": 1447, "Title": "GSK-FAS30007", "Description": "A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms." },{ "PostingID": 1465, "Title": "GSK-FPD40009", "Description": "A Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Fluticasone Propionate Inhalation Powder (250mcg QD) and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Receiving Short Acting Beta Agonist Alone" },{ "PostingID": 1476, "Title": "GSK-SAM40036", "Description": "A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects" },{ "PostingID": 1562, "Title": "BI-1218.15", "Description": "Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone" },{ "PostingID": 1568, "Title": "BI-1218.35", "Description": "Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug" },{ "PostingID": 1571, "Title": "BI-1218.40", "Description": "Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM" },{ "PostingID": 1634, "Title": "GSK-29060/449", "Description": "A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression" },{ "PostingID": 1676, "Title": "GSK-25000/557", "Description": "A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Three Times Daily for 7 or 10 Days for the Treatment of Bacterial Community Acquired Pneumonia in Adults." },{ "PostingID": 1679, "Title": "GSK-25000/600", "Description": "A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 days in the Treatment of Adults with Bacterial Community Acquired Pneumonia." },{ "PostingID": 1681, "Title": "GSK-105517/367", "Description": "A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Administration of Modified Release COREG or Placebo on Blood Pressure in Essential Hypertension Patients" },{ "PostingID": 1733, "Title": "GSK-FFR100012", "Description": "A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to 11 years of age with perennial allergic rhinitis (PAR)." },{ "PostingID": 1736, "Title": "GSK-FFR106080", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)" },{ "PostingID": 1737, "Title": "GSK-HZA106837", "Description": "A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma" },{ "PostingID": 1804, "Title": "GSK-LAM100034", "Description": "A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures" },{ "PostingID": 1806, "Title": "GSK-SCA100223", "Description": "A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder" },{ "PostingID": 1809, "Title": "GSK-NPP30004", "Description": "A Multicenter, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of Lamotrigine 200mg/day, 300mg/day, and 400mg/day Compared with Placebo in Subjects with Painful Diabetic Neuropathy" },{ "PostingID": 1890, "Title": "GSK-SKF-101468/191", "Description": "A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS)" },{ "PostingID": 1906, "Title": "GSK-101468/249", "Description": "A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)" },{ "PostingID": 1930, "Title": "GSK-AC4115408", "Description": "A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease" },{ "PostingID": 1941, "Title": "GSK-HS230018", "Description": "An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects" },{ "PostingID": 1957, "Title": "LILLY-F1D-MC-HGHB", "Description": "A Double-Blind Randomised Comparison of the Efficacy and Safety of Short Acting Intramuscular Olanzapine, Short Acting Intramuscular Haloperidol and Intramuscular Placebo in Patients with Schizophrenia" },{ "PostingID": 1969, "Title": "BI-9.178", "Description": "JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme" },{ "PostingID": 1974, "Title": "BI-1218.61", "Description": "Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone" },{ "PostingID": 1979, "Title": "BI-1182.12", "Description": "Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)" },{ "PostingID": 2049, "Title": "BI-205.266", "Description": "Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 2058, "Title": "BI-1182.48", "Description": "Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)" },{ "PostingID": 2098, "Title": "LILLY-F1D-MC-HGMP", "Description": "Efficacy and Safety of Olanzapine in the Treatment of Patients with Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison with Placebo" },{ "PostingID": 2107, "Title": "BI-502.254", "Description": "Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)" },{ "PostingID": 2146, "Title": "*BI-1123.11", "Description": "A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting" },{ "PostingID": 2147, "Title": "BI-205.137", "Description": "Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)" },{ "PostingID": 2149, "Title": "BI-205.227", "Description": "Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 2226, "Title": "LILLY-B4Z-US-LYBP", "Description": "A Randomized, Double-Blind, Placebo-Controlled Study of Atomoxetine
Hydrochloride in Children and Adolescents with Attention-Deficit/Hyperactivity
Disorder and Comorbid Anxiety" },{ "PostingID": 2235, "Title": "LILLY-B4Z-MC-LYAO", "Description": "A Phase III Randomized, Double-Blind Comparison of Placebo and
Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-
Deficit/Hyperactivity Disorder." },{ "PostingID": 2257, "Title": "TAKEDA-SYR-322_303", "Description": "A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes" },{ "PostingID": 2264, "Title": "TAKEDA-SYR-322-TZD-009", "Description": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Diabetes Mellitus, Type 2" },{ "PostingID": 2298, "Title": "TAKEDA-01-05-TL-322OPI-001", "Description": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS), in Subjects With Type 2 Diabetes" },{ "PostingID": 2347, "Title": "TAKEDA-C13006", "Description": "A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis" },{ "PostingID": 2393, "Title": "BI-1222.14", "Description": "Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II" },{ "PostingID": 2421, "Title": "GSK-207499/125", "Description": "A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)." },{ "PostingID": 2445, "Title": "GSK-712753/002", "Description": "A phase III, 24 week, multi-centre, randomised, double-blind, parallel group, dose escalation study of Avandamet (rosiglitazone/metformin) and high dose metformin monotherapy in subjects with poorly controlled type 2 diabetes mellitus" },{ "PostingID": 2446, "Title": "GSK-712753/003", "Description": "A Phase III Multi-Centre, Double-Blind, Randomised, Parallel-Group, Dose Escalation Study Comparing the Effects of 32 Weeks Administration of Avandamet and Metformin on Hba1c Targets in Subjects With Mild Type 2 Diabetes Mellitus" },{ "PostingID": 2469, "Title": "LILLY-B1Y-EW-HCHQ", "Description": "A Double-Blind Placebo-Controlled Study of Fluoxetine and Clomipramine in the Treatment of Panic Disorder" },{ "PostingID": 2485, "Title": "TAKEDA-01-06-TL-491-011", "Description": "A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension" },{ "PostingID": 2502, "Title": "TAKEDA-TAK-491_301", "Description": "A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension" },{ "PostingID": 2514, "Title": "BI-1245.20", "Description": "Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes" },{ "PostingID": 2523, "Title": "GSK-BRL-029060/CPMS- 116", "Description": "Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder" },{ "PostingID": 2524, "Title": "GSK-MY- 1028/BRL-029060/1/CPMS-118", "Description": "Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder" },{ "PostingID": 2525, "Title": "GSK-MY1047/BRL-029060/1/CPMS-120", "Description": "A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder." },{ "PostingID": 2534, "Title": "GSK-PAR 029060-502", "Description": "A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia" },{ "PostingID": 2539, "Title": "GSK-PAR 648", "Description": "A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD)" },{ "PostingID": 2582, "Title": "LILLY-F1J-MC-HMDV", "Description": "Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder" },{ "PostingID": 2609, "Title": "BI-248.520", "Description": "Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients" },{ "PostingID": 2614, "Title": "BI-107.258", "Description": "A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis" },{ "PostingID": 2646, "Title": "ROCHE-WA22908", "Description": "A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylosing spondylitis (AS) who have had an inadequate response to previous TNF blocker therapy" },{ "PostingID": 2650, "Title": "LILLY-H3E-MC-JMHD", "Description": "PointBreak: a Randomized Phase III Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-small Cell Lung Cancer" },{ "PostingID": 2746, "Title": "ASTELLAS-178-CL-074", "Description": "A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive bladder." },{ "PostingID": 2748, "Title": "ASTELLAS-178-CL-046", "Description": "A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects with Symptoms of Overactive Bladder." },{ "PostingID": 2817, "Title": "GSK-49653/135", "Description": "2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy" },{ "PostingID": 2824, "Title": "GSK-BRL-049653/375", "Description": "A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects." },{ "PostingID": 2929, "Title": "BI-1222.52", "Description": "Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®" },{ "PostingID": 3010, "Title": "GSK-SUM30046", "Description": "A randomised, double-blind, single-attack, placebo-controlled, parallel group evaluation of the efficacy and tolerability of sumatriptan Fast Disintegrating Tablets (FDT) 50 mg and 100 mg versus placebo during the mild pain phase of a migraine attack." },{ "PostingID": 3030, "Title": "LILLY-B3D-US-GHBZ", "Description": "Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis" },{ "PostingID": 3037, "Title": "BI-1199.34", "Description": "Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II" },{ "PostingID": 3097, "Title": "*BI-135.312", "Description": "ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset" },{ "PostingID": 3147, "Title": "GSK-29060/689", "Description": "A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder" },{ "PostingID": 3178, "Title": "LILLY-B9E-MC-JHGA", "Description": "A Randomized Phase 3 Study of Gemcitabine plus Cisplatin versus MVAC Chemotherapy in Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium." },{ "PostingID": 3204, "Title": "LILLY-H3E-MC-JMEN", "Description": "A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer" },{ "PostingID": 3217, "Title": "ASTELLAS-9463-EC-0001", "Description": "Randomized, Open-label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Infections in High Risk Liver Transplant Recipients." },{ "PostingID": 3264, "Title": "GSK-SAS30024", "Description": "A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ..." },{ "PostingID": 3409, "Title": "GSK-ARI40007", "Description": "A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study Investigating the Effects of Either 4 or 6 Weeks Dutasteride 0.5mg Daily on Peri-Operative Bleeding Following Transurethral Resection of the Prostate (TURP) in Subjects with Benign Prostatic Hyperplasia (BPH)." },{ "PostingID": 3446, "Title": "GSK-275833/032", "Description": "A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical SB-275833 Ointment, 1%, Applied Twice Daily" },{ "PostingID": 3493, "Title": "GSK-TXA112495", "Description": "A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of TREXIMA™* in the Acute Treatment of Migraine Headaches" },{ "PostingID": 3616, "Title": "GSK-LOV111858", "Description": "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects" },{ "PostingID": 3650, "Title": "GSK-480848/033", "Description": "A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)." },{ "PostingID": 3687, "Title": "ROCHE-WA17045", "Description": "A randomized, double-blind study to evaluate the effect on treatment response of MabThera in combination with methotrexate, compared to methotrexate monotherapy, in patients with active rheumatoid arthritis" },{ "PostingID": 3698, "Title": "BI-1218.65", "Description": "Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy" },{ "PostingID": 3799, "Title": "GSK-393229/028", "Description": "A Multi-Center, Randomized, Phase 3 Study of Rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma" },{ "PostingID": 3800, "Title": "GSK-DB2114634", "Description": "A 24-week randomised, double-blind and placebo-controlled study to evaluate the efficacy and safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder compared with placebo Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler in subjects with Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 3814, "Title": "ROCHE-FVF4166G", "Description": "A PHASE III, MULTICENTER, RANDOMIZED, sham CONTROLLED STUDY OF THE efficacy and SAFETY OF RANIBIZUMAB compared to Sham IN SUBJECTS WITH macular edema secondary to central retinal vein occlusion" },{ "PostingID": 3824, "Title": "LILLY-H9X-MC-GBDC", "Description": "The Impact of LY2189265 versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)" },{ "PostingID": 3851, "Title": "ROCHE-AVF3671G", "Description": "A randomized, Double-BLIND, Placebo-controlled, phase IIIb trial comparing BEVACIZUMAB therapy WITH OR WITHOUT ERLotInib AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB for the first-line treatment of Locally Advanced, Recurrent, or metastatic nON SMALL CELL LUNG CANCER" },{ "PostingID": 3870, "Title": "BI-1100.1287", "Description": "Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women" },{ "PostingID": 3942, "Title": "GSK-105-123", "Description": "Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset). A multicentre, double-blind, placebo-controlled, parallel group study." },{ "PostingID": 3943, "Title": "GSK-105-040", "Description": "A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients" },{ "PostingID": 3945, "Title": "GSK-USA30226", "Description": "A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days." },{ "PostingID": 3951, "Title": "GSK-200109", "Description": "A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study 1" },{ "PostingID": 3961, "Title": "BI-1200.42", "Description": "LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib" },{ "PostingID": 4217, "Title": "GSK-GLP113121", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 4238, "Title": "GSK-PCR112810", "Description": "A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder" },{ "PostingID": 4274, "Title": "LILLY-H9X-MC-GBDG", "Description": "A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)" },{ "PostingID": 4359, "Title": "LILLY-H6D-MC-LVBO", "Description": "A Randomized, Double-Blind, Placebo-Controlled Study of IC351 (LY450190) Compared with Sildenafil for the Treatment of Patients with Male Erectile Dysfunction" },{ "PostingID": 4370, "Title": "LILLY-H6D-MC-LVCV", "Description": "A Randomized, Double-Blind,
Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (IC351) (5 mg and 10 mg) Administered Once Daily to Men with Erectile Dysfunction" },{ "PostingID": 4453, "Title": "LILLY-I1F-MC-RHBA", "Description": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis. UNCOVER-2" },{ "PostingID": 4467, "Title": "LILLY-H6D-MC-LVGY", "Description": "PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension" },{ "PostingID": 4476, "Title": "LILLY-H6D-MC-LVID", "Description": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia" },{ "PostingID": 4478, "Title": "ASTELLAS-178-CL-090", "Description": "A Phase 3, Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron (YM178) in Asian Patients with Symptoms of Overactive Bladder" },{ "PostingID": 4517, "Title": "GSK-RTG114855", "Description": "A randomised, double-blind, placebo-controlled, parallel-group, multicentre study to determine the efficacy and safety of 2 doses of retigabine immediate release (900 mg/day and 600 mg/day) used as adjunctive therapy in adult Asian subjects with drug-resistant partial-onset seizures." },{ "PostingID": 4533, "Title": "LILLY-14X-IE-JFCC", "Description": "A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (SQUIRE)" },{ "PostingID": 4545, "Title": "BI-1275.1", "Description": "Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients" },{ "PostingID": 4547, "Title": "ROCHE-PIPF-004", "Description": "A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis" },{ "PostingID": 4550, "Title": "ROCHE-BO22589", "Description": "A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer" },{ "PostingID": 4551, "Title": "ROCHE-BO25734", "Description": "A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy" },{ "PostingID": 4573, "Title": "GSK-201135", "Description": "201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily with Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down from a Maintenance Therapy with RELVAR® inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects" },{ "PostingID": 4609, "Title": "ASTELLAS-1941-CL-0105", "Description": "Phase III Study of ASP1941 -A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus-" },{ "PostingID": 4636, "Title": "GSK-200820", "Description": "A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)" },{ "PostingID": 4702, "Title": "BI-1047.16", "Description": "Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy" },{ "PostingID": 4721, "Title": "SANOFI-EFC12626", "Description": "A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin / GetGoal Duo-2" },{ "PostingID": 4725, "Title": "SANOFI-EFC6016", "Description": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin / GETGOAL-L" },{ "PostingID": 4790, "Title": "GSK-109493", "Description": "GSK1572932A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer" },{ "PostingID": 4802, "Title": "ROCHE-ML22367", "Description": "(AVATAR) A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer." },{ "PostingID": 4867, "Title": "TAKEDA-TAK-875_302", "Description": "A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK 875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes" },{ "PostingID": 4873, "Title": "TAKEDA-TAK-375SL_203", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects" },{ "PostingID": 4878, "Title": "GSK-200862", "Description": "A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control" },{ "PostingID": 4891, "Title": "LILLY-H7T-MC-TADO", "Description": "A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease." },{ "PostingID": 4926, "Title": "SANOFI-EFC11785", "Description": "Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen" },{ "PostingID": 4956, "Title": "GSK-CTT116853", "Description": "A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (with an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning via a Dry Powder Inhaler with Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily via a Reservoir Inhaler in Subjects with Chronic Obstructive Pulmonary Disease" },{ "PostingID": 4981, "Title": "BAYER-15982", "Description": "A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib (RESORCE)" },{ "PostingID": 5013, "Title": "LILLY-B9E-US-S302", "Description": "Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma" },{ "PostingID": 5038, "Title": "GSK-123-006", "Description": "A multicenter, double-blind, placebo-controlled trial evaluating oral 256U87 for the treatment of herpes zoster in immunocompetent patients less than 50 years old" },{ "PostingID": 5067, "Title": "ROCHE-MO17527 (L_9570)", "Description": "A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma" },{ "PostingID": 5093, "Title": "GSK-106377", "Description": "An randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of dutasteride 0.5mg once daily for 6 months in the treatment of male subjects with androgenetic alopecia (Norwood-Hamilton classification type IIIv, IV and V)" },{ "PostingID": 5098, "Title": "GSK-ARI114265", "Description": "A randomized, double-blind, parallel group study to compare the efficacy and safety of combination treatment with dutasteride (0.5mg) and tamsulosin (0.2mg) with tamsulosin (0.2mg) monotherapy, administered once daily for 2 years, on the improvement of symptoms and health outcomes in men with moderate to severe benign prostatic hyperplasia" },{ "PostingID": 5105, "Title": "GSK-116697", "Description": "Open-label study to evaluate the safety and immunogenicity of GSK Biologicals' Herpes Zoster vaccine GSK1437173A in adults aged 50 years or older" },{ "PostingID": 5122, "Title": "GSK-SMS40026", "Description": "A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of 12 Months Treatment With Salmeterol (50mcg bd), Delivered via the DISKUS* Inhaler, on the Incidence of Moderate and Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) When Added to Their Usual Treatment Regimen" },{ "PostingID": 14465, "Title": "*SANOFI-MO17527/L_9570", "Description": "A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma" },{ "PostingID": 14470, "Title": "TAKEDA-TAK-875-306", "Description": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events (TERMINATED)" },{ "PostingID": 14472, "Title": "ROCHE-YO25121", "Description": "A multicenter, open-label, randomized Phase III study to evaluate the efficacy and safety of Erlotinib (Tarceva®) versus gemcitabine/cisplatin as the first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC) patients with mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) in their tumors." },{ "PostingID": 14548, "Title": "GSK-200812", "Description": "A phase IIIB, 24-week randomised, double-blind study to compare ‘closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD)" },{ "PostingID": 14579, "Title": "ROCHE-GO28915", "Description": "A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy" },{ "PostingID": 14594, "Title": "ROCHE-WA21093", "Description": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis" },{ "PostingID": 16038, "Title": "GSK-111482", "Description": "GSK2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma" },{ "PostingID": 16076, "Title": "BI-1237.16", "Description": "To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways" },{ "PostingID": 16077, "Title": "BI-1237.19", "Description": "A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]" },{ "PostingID": 16127, "Title": "LILLY-I1F-MC-RHBP", "Description": "A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis (IXORA-P)" },{ "PostingID": 16146, "Title": "ROCHE-WA20494", "Description": "A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment" }]